{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:50:43Z","timestamp":1791399043544,"version":"4.3.3"},"update-to":[{"DOI":"10.1371\/journal.pmed.1005262","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000}}],"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010425","name":"Tri-Service General Hospital","doi-asserted-by":"publisher","award":["TSGH-D-115176"],"award-info":[{"award-number":["TSGH-D-115176"]}],"id":[{"id":"10.13039\/501100010425","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005937","name":"Cheng Hsin General Hospital Foundation","doi-asserted-by":"publisher","award":["CHNDMU-115-02"],"award-info":[{"award-number":["CHNDMU-115-02"]}],"id":[{"id":"10.13039\/501100005937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Preclinical evidence identifies the serotonin transporter (SERT, encoded by SLC6A4) as an immune checkpoint on CD8+\u2009T cells, with selective serotonin reuptake inhibitors (SSRIs) enhancing antitumor immunity in synergy with anti-programmed cell death protein 1 (anti-PD-1) therapy. Whether this translates into clinical benefit for patients receiving immune checkpoint inhibitors (ICIs) is unknown. Using a target trial emulation framework, we compared outcomes between SSRI users and benzodiazepine (BZD) users among patients with a solid tumor and depression or anxiety who were receiving an ICI. Separately, in The Cancer Genome Atlas (TCGA), which covers a different set of patients, we examined how SLC6A4 expression related to tumor immune-cell infiltration across cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>\n                      We emulated a target trial in the TriNetX federated electronic health record network (over 187 million patients), comparing SSRI with BZD treatment at first ICI administration under an intention-to-treat-analogue estimand. Eligible patients were adults with a solid tumor, a first ICI administration between 2015 and 2025, and a depressive or anxiety disorder recorded within the prior 365 days. Exposure required an active SSRI or BZD prescription overlapping the index date or starting within the preceding 90 days, not necessarily on that date. The primary outcome was 2-year overall survival; 20 secondary outcomes across 4 mechanistic pathways were prespecified. Propensity score matching (1:1) on 49 baseline covariates yielded 1,567 pairs. Estimates are hazard ratios (HRs) with 95% confidence intervals (CIs). Transcriptomic analyses used TCGA (8,272 tumor samples from 8,172 patients, 20 tumor types). Among 3,134 matched patients, SSRI use was associated with lower 2-year all-cause mortality (23.5% versus 34.4%; HR 0.627; 95% CI [0.549, 0.716];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001;\n                      <jats:italic>E<\/jats:italic>\n                      -value 2.57). Composite immune-related adverse events (irAEs) were more frequent with SSRI use (HR 1.162; 95% CI [1.039, 1.299];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008), driven by thyroid dysfunction (HR 1.199; 95% CI [1.053, 1.366];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006), without increases in hepatitis, pneumonitis, or colitis (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.09). Newly coded distant metastases were less frequent in the SSRI group (HR 0.629; 95% CI [0.487, 0.811];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and the 3 prespecified negative controls (nephrolithiasis, cholelithiasis, cataract) showed null associations (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.76). All 5 individually analyzable SSRIs were associated with lower mortality (HR range 0.61 to 0.71). In TCGA, SLC6A4 expression was inversely correlated with T-cell inflammation in 13 of 20 cancer types, and this organ-level pattern matched that of organ-specific irAEs. The main limitation is residual confounding: performance status, a clinician\u2019s rating of everyday functional ability that strongly predicts cancer survival, is not recorded in the network, and BZDs are prescribed in different circumstances from SSRIs, so the groups may differ in ways matching cannot capture. The TCGA analyses used bulk tumor tissue from patients not treated with ICIs, so they cannot localize SLC6A4 to particular cells or show that SSRIs alter the tumor microenvironment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, SSRI use was associated with lower mortality and organ-selective immune activation compared with BZD use among ICI-treated patients with psychiatric comorbidity. Transcriptomic evidence supports biological plausibility. These findings warrant prospective evaluation of SSRI repurposing as an ICI adjuvant.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pmed.1005262","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:36:59Z","timestamp":1790703419000},"page":"e1005262","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selective serotonin reuptake inhibitors and immune checkpoint blockade in solid tumors: A target trial emulation with pan-cancer transcriptomic analyses"],"prefix":"10.1371","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0280-6417","authenticated-orcid":true,"given":"Po-Huang","family":"Chen","sequence":"first","affiliation":[{"name":"Tri-Service General Hospital, National Defense Medical University","place":["Taipei, Taiwan"],"department":["Division of Hematology and Oncology, Department of Internal Medicine"]},{"name":"Tri-Service General Hospital, National Defense Medical University","place":["Taipei, Taiwan"],"department":["Department of Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3953-5243","authenticated-orcid":true,"given":"Ming-Shen","family":"Dai","sequence":"additional","affiliation":[{"name":"Tri-Service General Hospital, National Defense Medical University","place":["Taipei, Taiwan"],"department":["Division of Hematology and Oncology, Department of Internal Medicine"]},{"name":"Tri-Service General Hospital, National Defense Medical University","place":["Taipei, Taiwan"],"department":["Department of Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7970-3758","authenticated-orcid":true,"given":"Mao-Hsuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Cheng Hsin General Hospital","place":["Taipei, Taiwan"],"department":["Department of Psychiatry"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0552-569X","authenticated-orcid":true,"given":"Hsin-Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Chi Mei Medical Center","place":["Tainan, Taiwan"],"department":["Department of Family Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0692-7408","authenticated-orcid":true,"given":"Li-Ting","family":"Kao","sequence":"additional","affiliation":[{"name":"National Defense Medical University","place":["Taipei, Taiwan"],"department":["Graduate Institute of Life Sciences"]},{"name":"National Defense Medical University","place":["Taipei, Taiwan"],"department":["School of Pharmacy"]},{"name":"Tri-Service General Hospital","place":["Taipei, Taiwan"],"department":["Department of Pharmacy Practice"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6296-0689","authenticated-orcid":true,"given":"Tina Yi-Jin","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Beth Israel Deaconess Medical Center","place":["Boston, Massachusetts, United States of America"],"department":["Department of Obstetrics and Gynecology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3304-4643","authenticated-orcid":true,"given":"Hong-Jie","family":"Jhou","sequence":"additional","affiliation":[{"name":"Changhua Christian Hospital","place":["Changhua, Taiwan"],"department":["Neurological Institute"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6061-5168","authenticated-orcid":true,"given":"Cho-Hao","family":"Lee","sequence":"additional","affiliation":[{"name":"Tri-Service General Hospital, National Defense Medical University","place":["Taipei, Taiwan"],"department":["Division of Hematology and Oncology, Department of Internal Medicine"]},{"name":"Tri-Service General Hospital, National Defense Medical University","place":["Taipei, Taiwan"],"department":["Department of Oncology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"6382","key":"pmed.1005262.ref001","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"A Ribas","year":"2018","journal-title":"Science"},{"issue":"8","key":"pmed.1005262.ref002","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1470-2045(13)70244-4","article-title":"Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: A systematic review and meta-analysis","volume":"14","author":"AJ Mitchell","year":"2013","journal-title":"Lancet Oncol"},{"issue":"22","key":"pmed.1005262.ref003","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1002\/cncr.24561","article-title":"Depression as a predictor of disease progression and mortality in cancer patients: A meta-analysis","volume":"115","author":"JR Satin","year":"2009","journal-title":"Cancer"},{"issue":"1","key":"pmed.1005262.ref004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nri.2015.5","article-title":"The role of inflammation in depression: From evolutionary imperative to modern treatment target","volume":"16","author":"AH Miller","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"pmed.1005262.ref005","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fcvm.2017.00048","article-title":"The effects of serotonin in immune cells","volume":"4","author":"N Herr","year":"2017","journal-title":"Front Cardiovasc Med"},{"issue":"14","key":"pmed.1005262.ref006","article-title":"Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis","volume":"188","author":"B Li","year":"2025","journal-title":"Cell"},{"issue":"611","key":"pmed.1005262.ref007","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc8188","article-title":"Attenuation of peripheral serotonin inhibits tumor growth and enhances immune checkpoint blockade therapy in murine tumor models","volume":"13","author":"MA Schneider","year":"2021","journal-title":"Sci Transl Med"},{"issue":"1","key":"pmed.1005262.ref008","doi-asserted-by":"crossref","first-page":"2564734","DOI":"10.1080\/2162402X.2025.2564734","article-title":"Selective serotonin reuptake inhibitors enhance cancer immunosurveillance by pleiotropic mechanisms","volume":"14","author":"K Alvarez-Valadez","year":"2025","journal-title":"Oncoimmunology"},{"key":"pmed.1005262.ref009","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.103016","article-title":"Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1 TAMs","volume":"14","author":"F Dong","year":"2026","journal-title":"eLife"},{"issue":"5","key":"pmed.1005262.ref010","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/ph16050640","article-title":"Association between fluoxetine use and overall survival among patients with cancer treated with PD-1\/L1 immunotherapy","volume":"16","author":"J Magagnoli","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"21","key":"pmed.1005262.ref011","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71326","article-title":"Associations between anxiety or depression diagnosis and immune checkpoint inhibitor outcomes","volume":"14","author":"H Derry-Vick","year":"2025","journal-title":"Cancer Med"},{"issue":"6","key":"pmed.1005262.ref012","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41591-024-02929-4","article-title":"Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancer","volume":"30","author":"Y Zeng","year":"2024","journal-title":"Nat Med"},{"issue":"8","key":"pmed.1005262.ref013","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"MA Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"4","key":"pmed.1005262.ref014","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: Historical foundations and contemporary application","volume":"2","author":"JL Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"issue":"17","key":"pmed.1005262.ref015","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1001\/jama.2016.16435","article-title":"Confounding by indication in clinical research","volume":"316","author":"DN Kyriacou","year":"2016","journal-title":"JAMA"},{"issue":"9596","key":"pmed.1005262.ref016","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"E von Elm","year":"2007","journal-title":"Lancet"},{"issue":"12","key":"pmed.1005262.ref017","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent reporting of observational studies emulating a target trial-the TARGET statement","volume":"334","author":"AG Cashin","year":"2025","journal-title":"JAMA"},{"issue":"3","key":"pmed.1005262.ref018","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"PC Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"4","key":"pmed.1005262.ref019","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/aje\/kwm324","article-title":"Immortal time bias in pharmaco-epidemiology","volume":"167","author":"S Suissa","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"4","key":"pmed.1005262.ref020","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: Introducing the E-value","volume":"167","author":"TJ VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"7269","key":"pmed.1005262.ref021","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"DA Barbie","year":"2009","journal-title":"Nature"},{"issue":"8","key":"pmed.1005262.ref022","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"M Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"pmed.1005262.ref023","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"MS Rooney","year":"2015","journal-title":"Cell"},{"issue":"7693","key":"pmed.1005262.ref024","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"S Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"2","key":"pmed.1005262.ref025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"A Kotwal","year":"2020","journal-title":"Thyroid"},{"issue":"10","key":"pmed.1005262.ref026","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1365-2826.2008.01774.x","article-title":"The thyroid-brain interaction in thyroid disorders and mood disorders","volume":"20","author":"M Bauer","year":"2008","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"pmed.1005262.ref027","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0163-7258(97)00055-7","article-title":"Benzodiazepines, anxiety and immunity","volume":"75","author":"F Zavala","year":"1997","journal-title":"Pharmacol Ther"},{"issue":"28","key":"pmed.1005262.ref028","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"KC Arbour","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"pmed.1005262.ref029","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer","volume":"5","author":"DJ Pinato","year":"2019","journal-title":"JAMA Oncol"},{"issue":"3","key":"pmed.1005262.ref030","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: A tool for detecting confounding and bias in observational studies","volume":"21","author":"M Lipsitch","year":"2010","journal-title":"Epidemiology"},{"issue":"1","key":"pmed.1005262.ref031","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41698-021-00223-x","article-title":"Real-world data analyses unveiled the immune-related adverse effects of immune checkpoint inhibitors across cancer types","volume":"5","author":"F Wang","year":"2021","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"pmed.1005262.ref032","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70100","article-title":"Validation of immune-related adverse event (irAE) case definitions in a real-world lung cancer population","volume":"34","author":"JS Heyward","year":"2025","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"pmed.1005262.ref033","article-title":"Dearth of ICD codes for complications of immune checkpoint inhibitors impedes clinical care and research","volume":"7","author":"Y-MM Cheung","year":"2023","journal-title":"J Endocr Soc"}],"updated-by":[{"DOI":"10.1371\/journal.pmed.1005262","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000}}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1005262","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:00:39Z","timestamp":1791396039000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1005262"}},"subtitle":[],"editor":[{"given":"Tessho","family":"Maruyama","sequence":"first","affiliation":[{"name":"University of the Ryukyus: Ryukyu Daigaku","place":["JAPAN"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1005262","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}